N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

What Was Tested

This registered phase 2 trial tested NAD+.

The goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults.

It will also learn about the safety of drug nicotinamide riboside.

The main questions it aims to answer are: * Does drug nicotinamide riboside slow the progression of Alzheimer disease as measured by the Clinical Dementia Rating scale. * What medical problems do participants have when taking drug nicotinamide riboside?

It had two arms (groups): Nicotinamide Riboside (NR) (experimental) and Placebo (placebo comparator).

Placebo capsules, no active ingredients.

The registry classes the interventions as dietary supplement and other.

Who Took Part

The registry lists 270 planned participants were the target.

It was open to people of any sex aged from 50 years up to 85 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Diagnosis Early clinical AD, e.g. Stage 3 MCI or Stage 4 (mild AD dementia), as defined by the FDA, 2024. Diagnosed with AD within 2 years from baseline. Global CDR(33) 0.5-1 (inclusive) at enrollment. Age 50 to 85 years (inclusive) at the time of enrollment. A study partner with sufficient contact to be able to provide data on ADLs and assist the participant in study drug administration. -.

The full record lists 8 inclusion and 8 exclusion criteria; among the exclusions: diagnosis of dementia other than probable ad; abundant vascular pathology, i.e. fazekas \>2. or \>3 lacunar infarcts, stroke involving a major vascular territory, severe small vessel, or white matter disease; comorbidity that precludes study participation or data interpretation.

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2026-08-26 with completion listed for 2030-04-30.

It ran at 2 sites in Norway (2).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Disease severity assessed by the Clinical Dementia Rating scale (CDR) sum of boxes (time frame: From baseline to the end of treatment at 104 weeks).

It also tracked 6 secondary outcomes, for example Change from baseline in the MoCA score at Week 104, Change from baseline in Amsterdam ADL scale short version (A-IADL-Q-SV) at Week 104, Change from baseline in delayed recall performance on the CERAD 10-Word List at Week 104, Change from baseline in executive functioning as measured by Trail-Making Test Part B completion time at Week 104, Change from baseline in verbal fluency as measured by the COWAT (total correct words for F, A, S) at Week 104 and Change from baseline in Neuropsychiatric Inventory-Questionnaire (NPI-Q) at Week 104.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of NAD+ in 270 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.